TY - JOUR
T1 - Advancing the field of drug delivery
T2 - Taking aim at cancer
AU - Moses, Marsha A.
AU - Brem, Henry
AU - Langer, Robert
N1 - Funding Information:
We would like to thank Dr. Judah Folkman. The authors acknowledge the support of NIH CA52857 (H.B.), NIH RO1AT00650 (R.L., M.A.M.), NIH CA83106 (M.A.M.), NIH 2PO1CA455 (M.A.M.), and ACS RPG 97-013-04 (M.A.M.). We thank Kristin Gullage for her artwork and photography. Under a licensing agreement between Guilford Pharmaceuticals and the Johns Hopkins University, Dr. Brem is entitled to a share of royalty described in this work. Dr. Brem and the University own Guilford Pharmaceuticals stock, which is subject to certain restrictions under University policy. Dr. Brem is also a paid consultant to Guilford Pharmaceuticals. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
PY - 2003/11
Y1 - 2003/11
N2 - Drug delivery systems for cancer therapeutics have now been used by millions of patients and have resulted in the creation of new therapies as well as significantly improving existing ones. Here we discuss a number of the drug delivery systems that have been approved by regulatory authorities and that are currently in clinical use, such as controlled delivery of cancer therapeutics, local chemotherapy, polymer drug conjugates, liposomal systems, and transdermal drug delivery patches. The next generation of "smart" drug delivery approaches such as controlled release microchips are discussed as are some of the future challenges and directions in this field.
AB - Drug delivery systems for cancer therapeutics have now been used by millions of patients and have resulted in the creation of new therapies as well as significantly improving existing ones. Here we discuss a number of the drug delivery systems that have been approved by regulatory authorities and that are currently in clinical use, such as controlled delivery of cancer therapeutics, local chemotherapy, polymer drug conjugates, liposomal systems, and transdermal drug delivery patches. The next generation of "smart" drug delivery approaches such as controlled release microchips are discussed as are some of the future challenges and directions in this field.
UR - http://www.scopus.com/inward/record.url?scp=0344494508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0344494508&partnerID=8YFLogxK
U2 - 10.1016/S1535-6108(03)00276-9
DO - 10.1016/S1535-6108(03)00276-9
M3 - Review article
C2 - 14667500
AN - SCOPUS:0344494508
SN - 1535-6108
VL - 4
SP - 337
EP - 341
JO - Cancer cell
JF - Cancer cell
IS - 5
ER -